Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Corporate Update (December 2019)
20 slides from Bio-gene Technology's corporate update, Dec 13, 2019
Slide 1: Presentation on Breakthrough in Control of Resistant Mosquitoes
ASX ANNOUNCEMENT 13 DECEMBER 2019 PRESENTATION ON BREAKTHROUGH IN CONTROL OF RESISTANT MOSQUITOES Bio-Gene Technology Limited (ASX: BGT, ‘Bio-Gene’ or the ‘Company’) is pleased to release this slide presentation relating to the recent Bio-Gene announcement “Significant Breakthrough in Control of Res
Slide 2: Breakthrough in control of resistant mosquitos
ASX: BGT Breakthrough in control of resistant mosquitos 13 December 2019
Slide 3: The increasing problem of global vector-borne diseases
The increasing Incidence of Three Major Vector-borne Diseases problem of global vector-borne diseases Major vector-borne diseases Countries that have reported account for 17% of the estimated infections of global burden of communicable either Zika, Malaria and / or diseases & claim >700,000 lives De
Slide 4: Vector-borne diseases are a growing problem
Vector-borne diseases are a “The issue of vector-borne disease is a rapidly growing global growing problem problem due to increasing insecticide resistance, population growth, urbanisation, travel, and climate change. Currently more than half of the world’s population is at risk of vector-borne dise
Slide 5: Insecticide resistance
Insecticide Increasing number of resistant species New insecticides are increasingly elusive resistance >140,000 molecules must be Molecules Screened Species Resistant 700 586 insect species now 160,000 resistant to at least one screened to discover a new insecticide class 140,000 compound 600 120,0
Slide 6: New solutions are needed to address resistance & toxicity
New solutions are needed to address resistance & toxicity Increasing incidence of resistance threatens effectiveness of existing controls Significant concern over the toxicity of existing and new insecticides to the environment EU bans a number of Neonicotinoids, (the most widely used insecticide cl
Slide 7: Resistance recorded across mosquito species
Mosquito Species Infectious diseases spread Aedes sp. Anopheles sp. Culex sp. via mosquitoes Zika Virus ✔ - - 42 countries Dengue Fever ✔ - - 390m infections Yellow Fever ✔ - - 30,000 deaths Disease Carried Malaria - ✔ - 219m infections Resistance to commonly used 47 states in the US with insecticid
Slide 8: Malaria mosquito resistance
History of WHO-approved insecticides for adult Malaria Mosquito control Malaria mosquito resistance 1940's 1950's 1960's 1970's 1980's 1990's 2000's 2010's Chlorfenapyr Pirimiphos- Alpha- DDT Malathion Fenitrothion (2017) methyl cypermethrin Lindane Propoxur Bendiocarb Cyfluthrin Widespread resistan
Slide 9: Critical intervention methods
Critical intervention methods Contribution of Malaria Control Intervention in Africa Tarsal absorption Insecticide-treated bed nets (‘ITN’) via insecticide are the most common method to treated bed nets control Malaria mosquitoes 22% Insecticide-treated Bednets (ITN) At least 700 million ITNs have b
Slide 10: Bio-Gene is well placed to deliver a solution
Bio-Gene is well placed to deliver a solution
Slide 11: Bio-Gene's technology addresses market needs
• Flavocide™ is a ‘nature identical mimic’ of a natural compound that can be Bio-Gene’s Safe mass produced for vector control Chemistry technology • Low toxicity to bees & beneficial insects, favourable safety profile for use addresses market needs Efficacy • Testing to date confirms potential for c
Slide 12: A novel Mode of Action is key to addressing resistance
A novel Mode of The Problem The Solution Action is key to “Mosquito resistance to current insecticides is threatening the huge gains made so far in “Studies undertaken by Neurosolutions have demonstrated Flavocide has a unique mode addressing reducing deaths from malaria, so we desperately need effe
Slide 13: Testing Overview: Flavocide mosquito results
Testing Overview Flavocide • Bio-Gene has engaged Purdue University, world leaders in vector control, to evaluate Flavocide for control of mosquitoes carrying diseases such as Malaria, Dengue, Zika and mosquito results West Nile Virus • Recent studies have involved tarsal assays that demonstrated Fl
Slide 14: Flavocide results
Flavocide results Overview of Flavocide tarsal assay studies completed at Purdue University CLICK HERE TO PLAY MOSQUITO TESTING VIDEO Studies funded by Bio -Gene Technology Ltd. Statements are those of the principle investigator and do not represent the position of Purdue University 13
Slide 15: Purdue Tarsal Assay Summary
Purdue Purdue Tarsal Tarsal Assay Assay Studies demonstrate the potential for Flavocide to be used Summary as an insecticide for control of SP-resistant mosquitoes Summary Test Overview: • Tarsal assay used to assess the response of adult mosquitos ( Anopheles gambiae) to a surface treated with Flav
Slide 16: Purdue collective trial results
Purdue collective Bio-Gene now holds a completed suite of mosquito data trial results This latest trial highlights a major discovery in the control of resistant Malaria-carrying mosquitoes. This adds to previous work on other species that are vectors of other global vector-borne diseases. Flavocide
Slide 17: Commercialisation pathway
16 Commercialisation pathway Strategic approach In-house Testing & Data Generation • Suite of data now well developed, with compelling evidence of A efficacy of Flavocide against key vector mosquito species Progress Commercial Discussions Globally • Now pursuing discussions with Corporates, NGO’s, P
Slide 18: Executive summary
Executive summary Bio-Gene has a compelling value proposition in vector control Proven efficacy in Low toxicity to >5,000x less Novel Mode key mosquito vector beneficial insects toxic to bees of Action control methods Our proprietary chemistry represents a step-change for resistant pest control Stro
Slide 19: References
https://www.who.int/neglected_diseases/news/comprehensive_global_approach_against_vector-borne_diseases/en/ https://mosquitoreviews.com/learn/disease-death-statistics https://wwwnc.cdc.gov/travel/page/zika-information https://www.who.int/gho/malaria/malaria_003.png?ua=1 References https://www.cdc.go
Slide 20: Richard Jagger CEO richardj@bio-gene.com.au
Richard Jagger CEO (03) 9628 4178 richardj@bio-gene.com.au Roger McPherson CFO, Co. Sec. (03) 9628 4178 rogerm@bio-gene.com.au
Bio-Gene Technology — Corporate Update (December 2019) on 6ix